Last reviewed · How we verify
Shock-dependent hydrocortisone
Shock-dependent hydrocortisone is a corticosteroid that is administered in response to shock to reduce inflammation and support the body's response to stress.
Shock-dependent hydrocortisone is a corticosteroid that is administered in response to shock to reduce inflammation and support the body's response to stress. Used for Treatment of shock.
At a glance
| Generic name | Shock-dependent hydrocortisone |
|---|---|
| Sponsor | UMC Utrecht |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Critical Care |
| Phase | Phase 3 |
Mechanism of action
Corticosteroids like shock-dependent hydrocortisone work by binding to glucocorticoid receptors in the body, which then modulate the expression of various genes involved in the inflammatory response. This can help to reduce inflammation and prevent tissue damage in response to shock. However, the exact mechanism of action of shock-dependent hydrocortisone is not fully understood and may involve other pathways as well.
Approved indications
- Treatment of shock
Common side effects
- Adrenal insufficiency
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance (PHASE4)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia (PHASE1)
- Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (NA)
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |